Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 2057

Sort by

Sort Order Select

Journal Articles

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis

Herman van Besien, Neela Easwar, Michelle Demetres, Michelle Pasciolla, Tsiporah Shore, John Leonard, Juliet Barker, Peter Martin, Samuel Yamshon

Blood Adv (2025) 9 (23): 6063–6075.

https://doi.org/10.1182/bloodadvances.2025016291

Published: 2025

Includes: Supplemental data

Journal Articles

Progressive silent cerebral infarction is associated with stroke and persistent cognitive impairment in survivors of iTTP

Jia Yu, Jenna Brown, Jay Meade, Gloria F. Gerber, Michael B. Streiff, Peggy Kraus, Samuel Merrill, Allyson M. Pishko, Jennifer Yui, Rakhi P. Naik, Robert A. Brodsky, Doris D. Lin, Shruti Chaturvedi

Blood Adv (2025) 9 (23): 5945–5953.

https://doi.org/10.1182/bloodadvances.2025017274

Published: 2025

Journal Articles

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30 + peripheral T-cell lymphoma

Blood Adv (2025) 9 (23): 5976–5987.

https://doi.org/10.1182/bloodadvances.2024015282

Published: 2025

Includes: Supplemental data

Journal Articles

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

Blood Adv (2025) 9 (23): 6047–6058.

https://doi.org/10.1182/bloodadvances.2025017011

Published: 2025

Includes: Supplemental data

Journal Articles

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study

Blood Adv (2025) 9 (23): 5954–5964.

https://doi.org/10.1182/bloodadvances.2024014975

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF

Nicoletta C. Machin, Maria M. Brooks, Deborah Vehec, Dana Ivanco, Brandon Lawryk, Craig D. Seaman, Frederico Xavier, Sruti Shiva, Angela Verdoni, Margaret V. Ragni

Blood Adv (2025) 9 (23): 6031–6039.

https://doi.org/10.1182/bloodadvances.2025017046

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years

Qian Wei Liu, Fang Fang, Huiwen Xue, Tove Wästerlid, Karin E. Smedby, Xinyuan Liu

Blood Adv bloodadvances.2024015776.

https://doi.org/10.1182/bloodadvances.2024015776

Published: 2025

Includes: Supplemental data

Journal Articles

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea

Blood Adv bloodadvances.2025017239.

https://doi.org/10.1182/bloodadvances.2025017239

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC

Ahmad Rayes, Brent R. Logan, Xuerong Liu, Jasmeen Dara, Rebecca H. Buckley, Joseph H. Oved, Neena Kapoor, Malika Kapadia, Sharat Chandra, Caridad A. Martinez, Nancy Bunin, Shanmuganathan Chandrakasan, Karin Chen, Jeffrey J Bednarski, Hilary L. Haines, Hesham Eissa, Julie-An M. Talano, Michael D. Keller, Christen L Ebens, Sonali Chaudhury, Evan B. Shereck, Victor M. Aquino, Alan P Knutsen, Jessie L Alexander, Alfred P Gillio, Deepakbabu Chellapandian, Ami J. Shah, Holly K Miller, Mark T Vander Lugt, Christine M. Seroogy, Morna J. Dorsey, Talal Mousallem, Roberta Essom Parrott, Richard J O'Reilly, Paibel I. Aguayo-Hiraldo, Susan E Prockop, Blachy J. Dávila Saldaña, Monica S. Thakar, Lauri M. Burroughs, Troy R. Torgerson, Jennifer W Leiding, Rebecca A Marsh, Linda M Griffith, Michael A. Pulsipher, Donald B. Kohn, Luigi D Notarangelo, Morton J Cowan, Jennifer M Puck, Geoffrey D.E. Cuvelier, Jennifer Heimall, Elie Haddad, Sung-Yun Pai, Christopher C Dvorak

Blood Adv bloodadvances.2025016812.

https://doi.org/10.1182/bloodadvances.2025016812

Published: 2025

Includes: Supplemental data

Journal Articles

Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

David A Sallman, Amy F McLemore, Rami S. Komrokji, Hany Elmariah, Andrew T. Kuykendall, Nelli Bejanyan, Onyee Chan, Rawan Faramand, Joseph A Pidala, Sean J Yoder, Lia E Perez, Taiga Nishihori, Eric Padron, Hugo Fernandez, Jeffrey E. Lancet, Asmita Mishra

Blood Adv bloodadvances.2025017742.

https://doi.org/10.1182/bloodadvances.2025017742

Published: 2025

Includes: Supplemental data

Journal Articles

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

Blood Adv bloodadvances.2025017760.

https://doi.org/10.1182/bloodadvances.2025017760

Published: 2025

Includes: Supplemental data

Journal Articles

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

Blood Adv bloodadvances.2025017083.

https://doi.org/10.1182/bloodadvances.2025017083

Published: 2025

Includes: Supplemental data

Journal Articles

Dreaming of a Better Future: Drug Development in Myeloma

Sagar Lonial, Richa Parikh

Blood Adv bloodadvances.2024015740.

https://doi.org/10.1182/bloodadvances.2024015740

Published: 2025

Journal Articles

Deferral of immunosuppression in acquired hemophilia

Jerome Teitel, Jean St-Louis

Blood Adv (2025) 9 (22): 5913–5914.

https://doi.org/10.1182/bloodadvances.2025017953

Published: 2025

Journal Articles

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Inga M. Schimansky, Christiane Dobbelstein, Robert Klamroth, Christina Hart, Ulrich J. Sachs, Richard Greil, Paul Knöbl, Johannes Oldenburg, Wolfgang Miesbach, Christian Pfrepper, Karolin Trautmann-Grill, Patrick Möhnle, Katharina Holstein, Hermann Eichler, Sonja Werwitzke, Andreas Tiede

Blood Adv (2025) 9 (22): 5853–5860.

https://doi.org/10.1182/bloodadvances.2025017144

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

Blood Adv (2025) 9 (22): 5814–5827.

https://doi.org/10.1182/bloodadvances.2025017214

Published: 2025

Includes: Supplemental data

Journal Articles

Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia

Anna L. Hoppmann, Deborah M. Hurley, Stuart Cramer, Monique J. Brown, Rahul Ghosal, Anthony J. Alberg, Smita Bhatia

Blood Adv (2025) 9 (22): 5861–5869.

https://doi.org/10.1182/bloodadvances.2025017044

Published: 2025

Includes: Supplemental data

Journal Articles

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial

Blood Adv (2025) 9 (22): 5828–5836.

https://doi.org/10.1182/bloodadvances.2025017394

Published: 2025

Includes: Supplemental data

Journal Articles

An AI model classifies risks of early relapse post–CAR T-cell therapy in a multicenter real-world population with DLBCL

Michelle Wang, Krishna V. Komanduri, Debajyoti Datta, Ayan Patel, Barbee Whitaker, Artur Belov, Benjamin Rubin, Rohit Vashist, Rosa Rodriguez-Monguio, Pelin Cinar, Steven Anderson, Atul J. Butte

Blood Adv (2025) 9 (22): 5837–5852.

https://doi.org/10.1182/bloodadvances.2025016375

Published: 2025

Includes: Supplemental data

Journal Articles

Defining and treating KICS: experience from the largest cohort yet

Casey L. McAtee, Nader Kim El-Mallawany

Blood Adv (2025) 9 (22): 5736–5737.

https://doi.org/10.1182/bloodadvances.2025017869

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparative infection risk in CAR T vs bispecific antibodies in B-cell lymphoma: a systematic review and meta-analysis

Progressive silent cerebral infarction is associated with stroke and persistent cognitive impairment in survivors of iTTP

Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30 + peripheral T-cell lymphoma

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study

Impact of tranexamic acid on postpartum hemorrhage in type 1 von Willebrand disease treated with recombinant VWF

Clonal hematopoiesis may precede the diagnosis of aplastic anemia by several years

Humoral and cellular immune response after COVID-19 vaccination in patients with sickle cell disease on hydroxyurea

Outcomes Following Matched Sibling Donor Transplantation for Severe Combined Immunodeficiency: A Report from the PIDTC

Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

Dreaming of a Better Future: Drug Development in Myeloma

Deferral of immunosuppression in acquired hemophilia

Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A

Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis

Neighborhood socioeconomic status and overall survival among children with acute lymphoblastic leukemia

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial

An AI model classifies risks of early relapse post–CAR T-cell therapy in a multicenter real-world population with DLBCL

Defining and treating KICS: experience from the largest cohort yet

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only